COMMUNIQUÉS West-GlobeNewswire

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
03/05/2024
MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]
Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
03/05/2024
Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has [...]
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
03/05/2024
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35 [...]
Trading statement Q1 2024
03/05/2024
Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both [...]
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
03/05/2024
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
03/05/2024
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of [...]
Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions
03/05/2024
EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et [...]
LUKE Named to 10-Year $43B Defense Health Agency IDIQ for the Medical Q-Coded Support and Services-Next Generation Program
03/05/2024
ROCKLEDGE, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- LUKE, a trusted leader in healthcare staffing for the U.S. Government, is proud to announce it has received a 10-year indefinite-delivery/indefinite-quantity (IDIQ) [...]
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
02/05/2024
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
02/05/2024
Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05/2024
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Cellectis nomme Arthur Stril directeur financier par intérim
02/05/2024
NEW YORK, 02 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® [...]
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
02/05/2024
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02/05/2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference
02/05/2024
DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
02/05/2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today [...]
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
02/05/2024
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . ( [...]
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
02/05/2024
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. ( [...]
LeMaitre Q1 2024 Financial Results
02/05/2024
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided [...]

Pages